Table 3.
Overall and race-specific associations between ER staining levels and receipt of endocrine therapy in multivariable models adjusted for age, tumor size, node involvement, grade, stage, and chemotherapy among women with ER+/HER2− invasive breast cancer
| Predictors in multivariable modela | Overall (n = 1573) |
AAW (n = 855) |
EAW (n = 762) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value | |
| Race (AAW vs EAW) | 0.99 | 0.96–1.03 | 0.68 | – | – | – | – | – | – |
| ER level (1–10% vs. > 50%) | 0.79 | 0.72–0.86 | < 0.001 | 0.77 | 0.68–0.86 | < 0.001 | 0.83 | 0.71–0.98 | 0.027 |
| ER level (11–50% vs. > 50%) | 0.97 | 0.88–1.07 | 0.51 | 0.97 | 0.87–1.09 | 0.65 | 0.95 | 0.79–1.14 | 0.89 |
a
Adjusted for age at diagnosis, tumor size, node involvement, grade, stage, and chemotherapy